Transaction DateRecipientSharesTypePriceValue
9th February 2021Jack Y. Zhang11,927Open or private sale$18.93$225,775.72
8th February 2021Jack Y. Zhang13,452Open or private sale$18.89$254,049.09
5th February 2021Jack Y. Zhang15,507Open or private sale$18.94$293,721.19
4th February 2021Jack Y. Zhang25,570Open or private sale$18.89$483,019.86
3rd February 2021Jack Y. Zhang16,299Open or private sale$18.36$299,322.99
2nd February 2021Jack Y. Zhang13,817Open or private sale$18.66$257,821.07
1st February 2021Floyd F. Petersen639Open or private sale$18.26$11,668.91
1st February 2021Jack Y. Zhang24,114Open or private sale$18.29$441,119.81
19th January 2021William J Peters6,495Open or private sale$18.67$121,236.97
1st December 2020Richard K Prins50,000Open or private sale$2.04$102,000.00
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Ticker: AMPH
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
SEC Central Index Key (CIK): 1297184
Employees: 2078
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $87 M (18%)
Inventory, Net: $105 M (0%)
Assets, Current: $267 M (4%)
Property, Plant and Equipment, Net: $238 M (0%)
Other Assets, Noncurrent: $13 M (13%)
Assets: $600 M (2%)
Accounts Payable, Current: $22 M (-13%)
Accrued Liabilities, Current: $54 M (3%)
Liabilities, Current: $93 M (3%)
Other Liabilities, Noncurrent: $11 M (16%)
Liabilities: $158 M (-1%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $54 M (3%)
Retained Earnings (Accumulated Deficit): $120 M (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $5 M (10%)
Treasury Stock, Value: $1 M (16%)
Stockholders' Equity (Parent): $398 M (4%)
Liabilities and Equity: $600 M (2%)
Gross Margin: $33 M (0%)
Research and Development: $16 M (-48%)
Sales and Marketing: $4 M (-45%)
General and Administrative Expenses: $16 M (-40%)
Operating Income/Loss: $3 M (0%)
Other Income, net: $1 M (0%)
Provision for income taxes: $75 Th (0%)